Semaglutide is a pharmaceutical agent designed for the treatment of type 2 diabetes and obesity. It functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, enhancing insulin secretion and delaying gastric emptying. This dual action results in improved glycemic control and promotes weight loss, proving beneficial for patients requiring management of both conditions.
Semaglutide terms and researches guide
Welcome to Semaglutide 101, your comprehensive guide to understanding the revolutionary treatment for type 2 diabetes and weight loss. Dive into the science of GLP-1 receptors, explore the latest research, and compare semaglutide with similar medications. Whether you're a healthcare professional or someone seeking knowledge, this page is your go-to resource for all things semaglutide.
Learn more about semaglutide
and weight loss
The GLP-1 receptor is a protein found on the surface of certain cells in the body, including pancreatic cells. It is activated by the incretin hormone GLP-1 (glucagon-like peptide-1) to enhance the release of insulin, which lowers blood sugar levels. This receptor is a critical target for drugs treating type 2 diabetes and obesity, as it also slows gastric emptying and promotes satiety.
Mounjaro, known generically as tirzepatide, is a medication for type 2 diabetes that combines the actions of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists. It enhances blood sugar control and promotes weight loss by stimulating insulin release, inhibiting glucagon secretion, and reducing appetite.
Trulicity, with the active ingredient dulaglutide, is a once-weekly injectable prescription medicine designed for the management of type 2 diabetes. It is a GLP-1 receptor agonist that helps control blood sugar levels, supports weight loss, and is associated with cardiovascular benefits, such as reducing the risk of major cardiovascular events.
Wegovy, containing semaglutide, is a once-weekly injectable prescription medication approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. As a GLP-1 receptor agonist, it significantly reduces body weight by regulating appetite and calorie intake.
Ozempic, also based on the drug semaglutide, is an injectable prescription medicine used once weekly to improve blood sugar control in adults with type 2 diabetes. It functions as a GLP-1 receptor agonist, which aside from its glycemic regulatory roles, is also noted for its effectiveness in weight loss as a secondary benefit.
Current research observation about semaglutide
Semaglutide 2.4 mg for Weight Loss in Adults with Overweight or Obesity
The phase III STEP clinical program has made significant strides in the field of obesity treatment, highlighting that a 2.4 mg semaglutide dosage offers clinically meaningful and lasting weight loss, surpassing results from other available obesity agents. The study underscores the positive impact of semaglutide for weight loss, not just in shedding pounds but also in enhancing the quality of life and health of individuals with obesity or overweight, with or without type 2 diabetes (T2D).
Long-Term Effects of Semaglutide on Weight Loss and Related Outcomes in Adults with Overweight and Obesity
The utilization of semaglutide for weight loss has demonstrated promising outcomes, especially for patients with overweight or obesity. In a real-world clinical setting, the effects of semaglutide treatment have mirrored the impressive weight loss results seen in randomized clinical trials. This correlation strongly suggests the practical applicability and effectiveness of semaglutide in treating individuals struggling with weight issues.
Semaglutide for Weight Loss in Patients with Type 2 Diabetes Mellitus
In a comprehensive study involving 201 adolescents, most of whom were battling obesity, the effectiveness of semaglutide was put to the test. Out of all participants, an impressive 90% adhered to the treatment regimen until its completion. The treatment plan was distinctive, combining a once-weekly 2.4-mg dosage of semaglutide with targeted lifestyle interventions aimed at fostering healthier habits. Over the course of 68 weeks, the results were striking. Those in the semaglutide group witnessed a significant decrease in BMI, averaging a notable reduction of − 16.1%. This was in stark contrast to the placebo group, which only recorded a minimal change of 0.6%. The difference between the two groups was substantial, highlighting the efficacy of semaglutide in this context.
Get semaglutide prescription online
Accessing an Ozempic (Semaglutide) prescription online has never been easier. Begin by consulting with licensed physicians through Heally's telehealth platform, discussing your health goals and suitability for semaglutide. You will receive personalized care, get your prescription, and have it sent directly to your home, all from the comfort of your home. Start your journey toward better health with Heally today.